new review was published in Volume 13 of Oncoscience, titled “Human chorionic gonadotropin kinetics in choriocarcinoma: A clinical compass from diagnosis to disease surveillance and outcome prediction.”

The review highlights the importance of monitoring human chorionic gonadotropin (hCG) levels in patients with choriocarcinoma, an aggressive cancer that develops from placental tissue.

It explains how changes in this hormone over time can help clinicians assess treatment response, identify drug resistance and detect possible disease recurrence.

The review's first author is Mishu Mangla from the Department of Obstetrics and Gynaecology, and the corresponding author is Seetu Palo from the Department of Pathology and Laboratory Medicine at All India Institute of Medical Sciences, Bibinagar, Hyderabad, India.

Choriocarcinoma is a highly aggressive form of gestational trophoblastic cancer that can spread rapidly to other organs.

It often produces unusually high amounts of hCG, a hormone normally associated with pregnancy.

While hCG is widely known as a pregnancy marker, it also plays a central role in diagnosing and monitoring this cancer.

The review emphasises that tracking hCG levels over time provides more useful information than relying on a single measurement.

At diagnosis, hCG concentrations help assess disease risk and guide treatment decisions, including the selection of chemotherapy.

During treatment, hCG levels typically decline as the cancer responds to chemotherapy.

A rapid, sustained decrease generally indicates a favourable response, while levels that remain stable or begin rising may signal drug resistance or disease progression.

These patterns can help clinicians determine when further evaluation or a change in treatment may be needed.

Regular hCG testing also remains important after treatment.

Persistent or rising levels may indicate residual disease or recurrence, sometimes before changes become apparent through symptoms or imaging.

Continued monitoring therefore helps support early detection and timely clinical intervention.

The authors also examine different forms of hCG, particularly hyperglycosylated hCG and free beta-hCG, which may provide additional information about tumour behaviour and disease activity.

Hyperglycosylated hCG has been linked to cancer cell proliferation and invasion, making it a potential marker of aggressive disease and a subject of therapeutic research.

“Measurement of the proportion of the free β-subunit of hCG provides further distinction.”

However, hCG testing has limitations.

Differences between laboratory assays and interference from certain antibodies can produce misleading results.

Extremely high hormone concentrations can also occasionally cause falsely low readings, highlighting the need for careful interpretation and confirmation when test results do not match the clinical picture.

The review explores emerging approaches, including more precise tests for different hCG forms and the use of additional biomarkers such as circulating microRNAs and cell-free DNA.

Experimental strategies that directly target hCG, including antibodies and vaccines, are also being investigated, although their clinical effectiveness in choriocarcinoma remains uncertain.

Overall, the review reinforces the importance of hCG monitoring throughout choriocarcinoma care, from initial diagnosis to treatment and long-term follow-up.

Understanding how hormone levels change over time could support more informed clinical decisions, earlier recognition of treatment failure and improved disease surveillance.

Source: Impact Journals LLC